Little-Known Advisory Panel Slowing Psychedelic Research in California
Currently, the state of California has the largest number of clinical studies in the country, making up more than 25% of registered clinical trials within the United States. Despite this, numerous studies that involve substances under Schedule I and II haven’t begun, even after obtaining clearance from the U.S. Drug Enforcement Administration (DEA), the U.S. Food and Drug Administration and institutional review boards. This is mainly because of the Research Advisory Panel of California (RAP-C), established under state law as the California Research Advisory Panel back in 1965. The RAP-C encourages and coordinates further studies of psychedelics and marijuana. The…